Consistent with the beneficial effects of FGF21 on obesity and fatty liver disease, pharmacological FGF21 protects the pancreas from gluco-lipotoxicity and cytokine-induced damage, pancreatitis, and fibrosis both in the islet and acinar cell compartments, promoting both endocrine and exocrine functions of the pancreas in various mouse models, such as the Streptozotocin (STZ)-induced type 1 diabetes, ob/ob, db/db, and diet-induced obese (DIO) models [150,151,152,153,154,155]. This evidence concerns the gene FGF21 and obesity disorder.